Crizotinib: A review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer

Drugs

Volumn 73, Issue 18, 2013, Pages 2031-2051

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANAPLASTIC LYMPHOMA KINASE POSITIVE; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; REVIEW; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; QUALITY OF LIFE; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84892586739     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0142-z     Document Type: Review

References (118)

1. International Agency for Research on Cancer. GLOBOCAN 2008: estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. http://globocan.iarc.fr/. Accessed 31 Jul 2013.
2. D'Addario G, Fruh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v116-9.
3. Ozkaya S, Findik S, Dirican A, et al. Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med. 2012;4(6):1035-8.
4. Bonanno L, Favaretto A, Rugge M, et al. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs. 2011;71(17):2231-46.
5. Felip E, Cedres S, Checa E, et al. How to integrate current knowledge in selecting patients for first line in NSCLC? Ann Oncol. 2010;21(Suppl 7):vii230-3.
6. Larsen JE, Cascone T, Gerber DE, et al. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J. 2011;17(6):512-27.
7. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-80.
8. Thomas R, Wolf J. Personalized therapy of lung cancer. Onkologie. 2012;35(Suppl 1):14-9.
9. Vadakara J, Borghaei H. Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med. 2012;5:113-23.
10. Villaruz LC, Socinski MA. Personalized therapy for non-small cell lung cancer: which drug for which patient? Semin Thorac Cardiovasc Surg. 2011;23(4):281-90.
11. Vincent MD, Kuruvilla MS, Leighl NB, et al. Biomarkers that currently affect clinical practice: EGFR, ALK, MET. KRAS. Curr Oncol. 2012;19(Suppl 1):S33-44.
12. Rafael Sierra J, Tsao M-S. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(Suppl 1):S21-S35.
13. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-703.
14. Cardarella S, Ogino A, Nishino M, et al. Clinical, pathological and biological features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16): 4532-40.
15. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol. 2013;31(20):e341-4.
16. Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997-2003.
17. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382-4.
18. Bergethon K, Shaw AT, Ou SHI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863-70.
19. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570-9.
20. Minoo P, Wang H-Y. ALK-immunoreactive neoplasms. Int J Clin Exp Pathol. 2012;5(5):397-410.
21. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
22. Curran MP. Crizotinib: in locally advanced or metastatic nonsmall cell lung cancer. Drugs. 2012;72(1):99-107.
23. Ou SHI. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471-85.
24. Lee JA, Bubendorf L, Stahel RA, et al. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. Expert Rev Anticancer Ther. 2013;13(5):625-36.
25. Pfizer Limited. Xalkori 200 mg hard capsules: EU summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002489/WC500134759.pdf. Accessed 3 Jul 2013.
26. Zou HY, Li Q, Lee J, et al. Antitumor efficacy of crizotinib (PF-02341066), a potent and selective ALK and c-Met RTK inhibitor, in EML4-ALK driven NSCLC tumors in vitro and in vivo [abstract no. LB-390]. 102nd Annual Meeting of the American Association for Cancer Research; 2-6 Apr 2011; Orlando (FL).
27. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67(9):4408-17.
28. Sun Y, Nowak KA, Zaorsky NG, et al. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. Mol Cancer Ther. 2013;12(5):696-704.
29. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012;7(7):1086-90.
30. Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 2011;6(10):1624-31.
31. Ou SHI, Tan J, Yen Y, et al. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther. 2012;12(4):447-56.
32. Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol. 2011;3(6):279-91.
33. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12 Pt. 1):3314-22.
34. Yamazaki S, Vicini P, Shen Z, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther. 2012;340(3): 549-57.
35. Tumati V, Kumar S, Yu L, et al. Effect of PF-02341066 and radiation on non-small cell lung cancer cells. Oncol Rep. 2013;29(3):1094-100.
36. Li C, Alvey C, Bello A, et al. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol. 2011;29(Suppl; abstract no. e13065).
37. Johnson TR, Goulet L, Smith EB, et al. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects [abstract no. P83]. Drug Metab Rev. 2011;43:77.
38. Pfizer Inc. XALKORI (crizotinib) capsules, oral. US prescribing information. 2013. http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed 3 Jul 2013.
39. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443-5.
40. Tan W, Wilner KD, Bang YJ, et al. Pharmacokinetics of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J Clin Oncol. 2010;28 (Suppl; abstract no. 2596).
41. Wang E, Nickens D, Bello A, et al. Clinical implication of a population pharmacokinetic analysis of XALKORI (crizotinib) in 1,182 patients with non-small cell lung cancer (NSCLC) and 32 patients with other solid tumors [abstract no. MO07.04 plus oral presentation]. International Association for the Study of Lung Cancer, 15th World Conference on Lung Cancer; 27-30 Oct 2013; Sydney.
42. Nishio M, Hirsh V, Kim D-W, et al. Efficacy, safety, and patient-reported outcomes (PROs) with crizotinib versus chemotherapy in Asian patients in a phase III study of previously treated advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract no. O16.05 plus oral presentation]. International Association for the Study of Lung Cancer, 15th World Conference on Lung Cancer; 27-30 Oct 2013; Sydney.
43. Hirsh V, Blackhall FH, Kim D-W, et al. Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK ? non-small cell lung cancer. J Clin Oncol. 2013; 31(Suppl; abstract no. 8108).
44. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-94.
45. Pfizer Limited. An investigational drug, PF-02341066 is being studied versus standard of care in patients with advanced nonsmall cell lung cancer with a specific gene profile involving the anaplastic lymphoma kinase (ALK) gene [ClinicalTrials.gov identifier NCT00932893]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/ct2/show/results/ NCT00932893. Accessed 3 Jul 2013.
46. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Xalkori. International non-proprietary name: crizotinib. Procedure no. EMEA/H/C/002489. 2012. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Public-assessment-report/human/002489/WC500134761. pdf. Accessed 3 Jul 2013.
47. Hida T, Shi Y, Ahn MJ, et al. Exploratory subgroup analysis of crizotinib efficacy and safety in Asian and non-Asian patients with advanced ALK-positive non-small cell lung cancer (NSCLC) enrolled in a global phase II study [abstract]. J Thorac Oncol. 2012;7(11 Suppl 5):S454-5.
48. Schnell P, Safferman AZ, Bartlett CH, et al. Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK?) advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30(Suppl; abstract no. 7598).
49. Salgia R, Solomon BJ, Shaw AT, et al. Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib. J Clin Oncol. 2012;30(Suppl; abstract no. 7596).
50. Ou SHI, Tong WP, Azada M, et al. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer. 2013;119:1969-75.
51. Weickhardt AJ, Rothman MS, Salian-Mehta S, et al. Rapidonset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012;118(21): 5302-9.
52. Weickhardt AJ, Doebele RC, Purcell WT, et al. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013;119(30):2383-90.
53. Shaw AT, Solomon BJ, Mok T, et al. Effect of treatment duration on incidence of adverse events (AEs) in a phase III study of crizotinib versus chemotherapy in advanced ALKpositive non-small cell lung cancer (NSCLC) [abstract no. P2.11-041 plus poster]. International Association for the Study of Lung Cancer, 15th World Conference on Lung Cancer; 27-30 Oct 2013; Sydney.
54. Nelson R. Crizotinib receives conditional marketing approval in Europe. 2012. http://www.medscape.com/viewarticle/773280. Accessed 22 Aug 2013.
55. Novartis International AG. Novartis breakthrough therapy LDK378 shows a marked clinical response in patients with ALK? non-small cell lung cancer [media release]. 3 June 2013. http://hugin.info/134323/R/1706664/565008.pdf.
56. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14:590-8.
57. Nakagawa K, Kiura K, Nishio M, et al. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: updated safety and efficacy results from AF-001JP. J Clin Oncol. 2013; 31(Suppl; abstract no. 8033).
58. Camidge DR, Bazhenova L, Salgia R, et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncol. 2013;31(Suppl; abstract no. 8031).
59. Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013;19(11):3068-77.
60. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010; 28(33):4953-60.
61. Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011-9.
62. Crino L, Kim D-W, Riely GJ, et al. Initial phase 2 results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. Proc Am Soc Clin Oncol 2011; 29(Suppl; abstract no. 7514).
63. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004-12.
64. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): non-small cell lung cancer. Version 2. 2013. http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed 20 Aug 2013.
65. Pfizer. A clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with ALK positive non squamous cancer of the lung (PROFILE 1014) [ClinicalTrials.gov identifier NCT01154140]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/show/NCT01154140. Accessed 19 Aug 2013.
66. Pfizer. A study of crizotinib versus chemotherapy in previously untreated East Asian non-small cell lung cancer patients [ClinicalTrials. gov identifier NCT01639001]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/ show/NCT01639001. Accessed 19 Aug 2013.
67. Gainor JF, Varghese AM, Ou SHI, et al. ALK rearrangements are mutually exclusive with mutations in EFGR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273-81.
68. Shaw A, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-53.
69. Kris MG, Johnson BE, Kwiatkowski A, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol. 2011;29(Suppl; abstract no. CRA7506).
70. Boehringer Ingelheim. Afatinib receives positive CHMP opinion for patients with EGFR mutation positive lung cancer in European Union [media release]. 26 July 2013. http://www.boehringer-ingelheim.com/news/news-releases/ press-releases/2013/26-july-2013-oncology.html.
71. GlaxoSmithKline. A phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced nonsmall cell lung cancer and BRAF mutations [ClinicalTrials.gov identifier NCT01336634]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/ct2/show/NCT 01336634. Accessed 12 Sep 2013.
72. Roche. Tarceva 25 mg film-coated tablets. EU summary of product characteristics. 2010. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000618/WC500033994.pdf. Accessed 20 Aug 2013.
73. AstraZeneca AB. IRESSA 250 mg film-coated tablets. EU summary of product characteristics. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/001016/WC500036358.pdf. Accessed 20 Aug 2013.
74. Boehringer Ingelheim. LUME-Lung 1: nintedanib plus chemotherapy extends the life of lung cancer patients with adenoc arcinoma [media release]. 3 June 2013. http://www.boehringeringelheim.com/news/news-releases/press-releases/2013/ 03-june-2013-oncology.html.
75. Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomized, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14(1):38-47.
76. Metro G, Minotti V, Crino L. Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? J Thorac Dis. 2012;4(6):635-8.
77. European Society for Medical Oncology. ESMO 2012 press release: phase III MISSION trial. Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer, EGFR status may help select patients who will benefit most. http://www.esmo.org/Conferences/Past-Conferences/ESMO-2012- Congress/News-Press-Releases/ESMO-2012-Press-Releases/Phase-III-MISSION-trial. Accessed 20 Aug 2013.
78. ArQule Inc. ArQule and Daiichi Sankyo announce discontinuation of phase 3 MARQUEE clinical trial in non-small cell lung cancer [media release]. 2 October 2012. http://investors.arqule.com/releasedetail.cfm?ReleaseID=710618.
79. Platt A, Elvin P, Morten J, et al. Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials. J Clin Oncol. 2013;31 (Suppl; abstract no. 8045).
80. Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/ fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2013;39(3):252-60.
81. Roche. Avastin 25 mg/ml concentrate for solution for infusion. EU summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000582/WC500029271.pdf. Accessed 20 Aug 2013.
82. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet. 2009;373(9764):1525-31.
83. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Assessment report for erbitux. International non-proprietary name/common name: cetuximab. Procedure no. EMEA/H/C/558/II/0029. 2010. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report- Variation/human/000558/WC500075683.pdf. Accessed 20 Aug 2013.
84. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Merck KGaA withdraws its application for an extension of the indication for Erbitux (cetuximab) [press release] 19 Sep 2012. http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/000558/wapp/ Post-authorisation/human-wapp-000145.jsp&mid=WC0b01ac058001d128.
85. Eli Lilly and Company. Lilly announces phase III necitumumab study meets primary endpoint of overall survival [media release]. 13 Aug 2013. http://newsroom.lilly.com/releasedetail.cfm?releaseid=784772.
86. Eli Lilly and Company. Lilly releases phase II results for monoclonal antibody ramucirumab in lung cancer [media release]. 29 September 2012. http://newsroom.lilly.com/releasedetail.cfm?releaseid=710172.
87. Eli Lilly and Company. A study of chemotherapy and ramucirumab vs. chemotherapy alone in second line non-small cell lung cancer participants who received prior first line platinum based chemotherapy [ClinicalTrials.gov identifier NCT01168973]. US National Institutes of Health, ClinicalTrials. gov. 2013. http://clinicaltrials.gov/show/NCT01168973. Accessed 20 Aug 2013.
88. Villaflor VM, Salgia R. Targeted agents in non-small cell lung cancer therapy: what is there on the horizon? J Carcinog. 2013;12:7. Available from: http://www.carcinogenesis.com/text.asp?2013/12/1/7/109253.
89. Casaluce F, Sgambato A, Maione P, et al. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol. 2013;8(1):55-67.
90. Yi ES, Chung J-H, Kulig K, et al. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review. Mol Diagn Ther. 2012;16(3):143-50.
91. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw. 2011;9(12):1335-41.
92. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823-59.
93. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461(3):245-57.
94. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012;106(6):1100-6.
95. Weickhardt AJ, Aisner DL, Franklin WA, et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer. 2013;119(8):1467-77.
96. Conklin CMJ, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8:45-51.
97. Martinez P, Hernandez-Losa J, Montero MA, et al. Fluourescent in situ hybridization and immunohistochemistry as diagnostic methods forALKpositive non-small cell lung cancer patients. PLoS ONE. 2013;8(1):e52261. doi:10.1371/journal.pone.0052261.
98. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged nonsmall cell lung cancer. Clin Cancer Res. 2012;18(5):1472-82.
99. Voena C, Chiarle R. The battle against ALK resistance: successes and setbacks. Expert Opin Investig Drugs. 2012;21(12): 1751-4.
100. Sasaki T, Janne PA. New strategies for treatment of ALKrearranged non-small cell lung cancers. Clin Cancer Res. 2011;17(23):7213-8.
101. Otterson GA, Riely GJ, Shaw AT, et al. Clinical characteristics of ALK ? NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): potential implications for management. J Clin Oncol. 2012;30(Suppl; abstract no. 7600).
102. Ou SHI, Zhou C, Ahn MJ, et al. Treatment of ALK-positive non-small cell lung cancer patients with crizotinib beyond disease progression: Clinical assessment and potential management implications [abstract]. J Thorac Oncol. 2012;7(11 Suppl 5):S446.
103. Crino L, Ahn MJ, Ou SHI, et al. Clinical experience with crizotinib in patients with advanced ALK-positive non-small cell lung cancer and brain metastases [abstract 3413 plus poster]. European Cancer Congress 2013; 27 Sep-1 Oct 2013; Amsterdam.
104. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363:1734-9.
105. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71(18):6051-60.
106. Doebele RC, Aisner DL, Le AT, et al. Analysis of resistance mechanisms to ALK kinase inhibitors in ALK? NSCLC patients. J Clin Oncol. 2012;30(Suppl; abstract no. 7504).
107. Tanizaki J, Okamoto I, Okabe T, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res. 2012;18(22):6219-26.
108. Ou SHI, Riely GJ, Tang Y, et al. Clinical benefit of continuing crizotinib beyond initial disease progression in patients with advanced ALK-positive non-small-cell lung cancer [abstract no. MO07.01 plus oral presentation]. International Association for the Study of Lung Cancer, 15th World Conference on Lung Cancer; 27-30 Oct 2013; Sydney.
109. Shaw AT, Solomon B. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. 2013. http://www.uptodate.com/contents/ anaplastic-lymphoma-kinasealk-fusion-oncogene-positive-non-small-cell-lung- cancer#H4. Accessed 19 Aug 2013.
110. Takeda M, Okamoto I, Nakagawa K. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol. 2013;8(5):654-7.
111. Matsuoka H, Kurata T, Okamoto I, et al. Clinical response to crizotinib retreatment after acquisition of drug resistance. J Clin Oncol. 2013;31(19):e322-3.
112. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807-14.
113. Becker A, Crombag L, Heideman DA, et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer. 2011;47(17):2603-6.
114. Data on file, Pfizer Inc., 2013.
115. van de Vooren K, Curto A, Garattini L. Optional copayments on anti-cancer drugs. BMJ. 2013;346:f349.
116. National Institute for Health and Care Excellence. Final appraisal determination: crizotinib for previously treated nonsmall cell lung cancer associated with an anaplastic lymphoma kinase fusion gene. 2013. http://www.nice.org.uk/nicemedia/live/13639/64900/64900.pdf. Accessed 21 Aug 2013.
117. National Institute for Health and Care Excellence. NICE consults on new draft recommendations for lung cancer drug [press release]. 26 March 2013. http://www.nice.org.uk/newsroom/pressreleases/CrizotinibACD.jsp. 2013.
118. Ou SHI, Kim D-W, Camidge DR, et al. Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC) [abstract no. MO07.03 plus oral presentation]. International Association for the Study of Lung Cancer, 15th World Conference on Lung Cancer; 27-30 Oct 2013; Sydney.